Emerging at the UK, retatrutide, a innovative molecule, is sparking considerable excitement within the scientific community regarding its ability for physique control . This dual GIP and GLP-1 agent agonist appears to deliver a considerable improvement over existing therapies, showing positive results in preliminary clinical trials . Researchers su